Overview

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
0
Participant gender:
Female
Summary
This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)
Phase:
Phase 3
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Dharmais National Cancer Center Hospital
Treatments:
Anastrozole
Aromatase Inhibitors
Exemestane
Fluorouracil
Letrozole
Tamoxifen
Criteria
Inclusion Criteria:

- IIIB/C and IV stage of breast cancer

- received neoadjuvant hormonal therapy or neoadjuvant chemotherapy

- had first and second biopsy (surgery) within 6 months

Exclusion Criteria:

- had mastectomy before treatment

- pregnant

- disagree to enter the study

- had been given hormonal therapy or chemotherapy before study

- had contra-indication of SOB for pre-menopausal patients